Cancer Vaccines and Tumor Immunity

A team of expert contributors takes a focused look at the emerging area of cancer vaccines and tumor immunity
Cancer vaccine development is one of the latest therapeutic tools being used in our fight against cancer. Cancer vaccine research has progressed from a small–scale academic enterprise to an applied science requiring a large clinical research infrastructure. Although cancer vaccines remain a work in progress, intriguing clinical results have been noted and new ideas continue to hold great promise for the field.
Cancer Vaccines and Tumor Immunity offers a review of the basic scientificdiscoveries that have moved forward into clinical trials. Presented in the context of real–world human research and experimentation, these major scientific advances demonstrate how our understanding of immune activation,T–regulatory cells, and autoimmunity will impact cancer vaccine design. The authors also explain how vaccination in the context of bone marrow transplantation will open new avenues for clinical study in the future.
Cancer Vaccines and Tumor Immunity is a one–stop resource for professionals and trainees in both academic and commercial institutions who are looking for a concise overview of the history of the field, current research, and likely advances that will shape the future of cancer vaccines. It also serves as a valuable supplementary text for graduate students studying in related fields.

Spis treści:
Contributors.
Foreword. Cancer Vaccines and Cancer Immunotherapy. A New Paradigm(Jeffrey Schlom).
PART I. INTRODUCTION.
Chapter 1. Cancer Vaccines. Progress and Promise (Rimas J. Orentas, Bryon Johnson, and James Hodge).
PART II. ADJUVANT THERAPY: ENHANCING THE ENDOGENOUS IMMUNE RESPONSE.
Chapter 2. Fully Synthetic Carbohydrate–Based Anti–Tumor Vaccines (Rebecca M. Wilson and Samuel J. Danishefsky).
Chapter 3. Bacillus Calmette–Guerin Immuno therapy of Genitourinary Cancer (Donald L. Lamm).
Chapter 4. Stimulation of Toll–like Receptor 9 for Enhancing Vaccination (Daniel E. Speiser and Arthur M. Krieg).
PART III. ANTIGEN–SPECIFIC THERAPY: NOVEL PRESENTATION OF PEPTIDE AND PROTEIN ANTIGENS.
Chapter 5. Polyepitope Vaccines (Corey Smith and Rajiv Khanna).
Chapter 6. Antigen–Specific Cancer Immunotherapy: HPV–Associated Cervical Cancer as a Model System (Shaw–Wei D. Tsen, Chien–Fu Hung, and T.–C. Wu).
Chapter 7. Poxviral Vectors for Cancer Vaccines: State of the Art (Elizabeth K. Wansley).
Chapter 8. Immunotherapeutic Strategies Against Cancer Using Listeria Monocytogenes as a Vector for Tumor Antigens (Nicholas C. Souders, Thorsten Verch and Yvonne Paterson).
Chapter 9. Coupling Innate and Adaptive Immunity with Yeast–based Cancer Immunotherapy (Sibyl Munson, Joanne Parker, Tom King, Yingnian Lu, Victoria Kelley, Zhimin Guo, Virginia Borges, and Alex Franzusoff).
PART IV. CELL–BASED THERAPY: USING CANCER CELLS AS A MEANS TO INDUCE SPECIFIC TUMOR IMMUNITY.
Chapter 10. Allogeneic Whole Cell Vaccines (John Copier and Angus Dalgleish).
Chapter 11. Jump–Starting Tumor Immunity with Breast Cancer Therapeutics (Leisha A. Emens).
Chapter 12. T–Regulatory Cell Manipulation in Tumor Immunotherapy (Jens Rüter, Brian G. Barnett, Ilona Kryczek, Michael J. Brumlik, Benjamin J. Daniel, George Coukos, Weiping Zou, Tyler J. Curiel).
Chapter 13. Tumor Vaccination after Autologous HSCT: What has been Learned from Experimental Models? (Weiqing Jing and Bryon D. Johnson).
Chapter 14. Vaccines in the Setting of Hematopoietic Stem Cell Transplantation (Ronald Gress and Claude Sportes).
Chapter 15. Intratumor Generation of Vigorous Antitumor Immune Responses (Ping Yu and Yang–Xin Fu).
Chapter 16. Cancer Immunotherapy: Untapping the Potential of Co–Stimulatory Molecules Be yond CTLA–4 (Mathew Augustine, and Lieping Chen).
PART V. DEFINING EFFECTIVE CLINICAL RESPONSES.
Chapter 17. Advances in Immune Monitoring Strategies for Cancer Vaccines and Immunotherapy (Seunghee Kim–Schulze, Moshe Ornstein and Howard L. Kaufman).
Chapter 18. Immune Evaluation of Cancer Vaccines (Theresa L. Whiteside).
Index.

Nota biograficzna:
Rimas J. Orentas, PhD, is Associate Professor in the Department of Pediatrics, Section of Hematology–Oncology, and holds joint appointments in the Departments of Medicine and Microbiology and Molecular Genetics at the Medical College of Wisconsin in Milwaukee, Wisconsin.
James W. Hodge, PhD, is a Senior Scientist in the Laboratory of Tumor Immunology and Biology at the National Cancer Institute in Bethesda, Maryland.
Bryon D. Johnson, PhD, is Associate Professor in the Department ofPediatrics, Section of Hematology–Oncology at the Medical College of Wisconsin in Milwaukee, Wisconsin.

Okładka tylna:

A team of expert contributors takes a focused look at the emerging area of cancer vaccines and tumor immunity
Cancer vaccine development is one of the latest therapeutic tools being used in our fight against cancer. Cancer vaccine research has progressed from a small–scale academic enterprise to an applied science requiring a large clinical research infrastructure. Although cancer vaccines remain a work in progress, intriguing clinical results have been noted and new ideas continue to hold great promise for the field.
Cancer Vaccines and Tumor Immunity offers a review of the basic scientificdiscoveries that have moved forward into clinical trials. Presented in the context of real–world human research and experimentation, these major scientific advances demonstrate how our understanding of immune activation,T–regulatory cells, and autoimmunity will impact cancer vaccine design. The authors also explain how vaccination in the context of bone marrow transplantation will open new avenues for clinical study in the future.
Cancer Vaccines and Tumor Immunity is a one–stop resource for professionals and trainees in both academic and commercial institutions who are looking for a concise overview of the history of the field, current research, and likely advances that will shape the future of cancer vaccines. It also serves as a valuable supplementary text for graduate students studying in related fields.